Louie Ngar Yee 4

What Happened

• Louie Ngar Yee, a director of MAIA Biotechnology, was granted 32,630 derivative securities (stock options) on June 30, 2026. The Form 4 reports the acquisition price as $0.00, i.e., the award was granted without an upfront cash payment. Per the filing footnote, the options represent the right to buy common stock, vest 100% on the grant date and are exercisable as of that date.

Key Details

• Transaction date: June 30, 2026; filing date: July 2, 2026.
• Transaction type/code: A (award/grant of derivative securities).
• Amount granted: 32,630 options; reported price: $0.00 (no cash paid at grant).
• Vesting/exercise: Footnote F1 — options vest 100% on grant date and are exercisable immediately.
• Shares owned after transaction: Not specified in the provided filing details.
• Timeliness: Filing was submitted July 2, 2026; no indication in the record provided that it was late.

Context

• This is an option grant (a derivative award) rather than an open-market purchase or sale. Exercising these options would require paying the exercise price (not specified in the provided lines) to convert options into shares; the grant itself does not create immediate proceeds or sales. Such awards are common for compensation or board incentives and should be interpreted as a disclosure of a granted right, not as an immediate bullish purchase of shares.